Examining organ aging in breast cancer patients undergoing chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the changes in P16INK4A expression and plasma proteomic signatures in women with early-stage breast cancer before and after receiving adjuvant chemotherapy. It aims to assess whether biological and accelerated immune aging, evaluated through T cells from peripheral blood, reflects aging in various organs. By comparing baseline characteristics with organ aging, the study seeks to identify patients at higher risk for chemotherapy-related complications, particularly those receiving regimens that include anthracyclines and taxanes. The findings could inform treatment adjustments to mitigate risks associated with chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥22years and \<66 years
* Diagnosed with early-stage breast cancer (The American Joint Committee on Cancer stages I-III).
* Understand and read English.
* Receive care at the study site.
* Able to understand and participate in study procedures for length of study.

Exclusion Criteria:

* Unable to provide consent, unable to communicate verbally.
* Unable to understand or read English.
* Enrolled in hospice care.

Where it's running

• University of North Carolina
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Hyman Muss, MD — UNC Lineberger Comprehensive Cancer Center
• Study coordinator: Allison Ross
• Email: allison_ross@med.unc.edu
• Phone: 919-966-3856

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.